Association between the Khorana risk score and all-cause mortality in Japanese patients with gastric and colorectal cancer: A retrospective cohort study

Table 2 Univariate analyses of all-cause death within 2 years

Variables	HR (95%CI)	P value
Age (≥ 65 yr vs < 65 yr)	1.22 (1.02-1.47)	0.034
KRS (intermediate vs low)	1.60 (1.21-2.13)	0.001
KRS (high vs low)	2.67 (1.91-3.73)	< 0.001
Sex (female vs male)	1.02 (0.79-1.30)	0.900
CAT (yes vs no)	1.01 (0.71-1.43)	0.965
ATE (yes vs no)	1.36 (0.60-3.05)	0.481
ECOG PS (≥ 2 vs 0-1)	4.05 (2.93-5.61)	< 0.001
Cancer type (CRC vs GC)	0.60 (0.47-0.76)	< 0.001
Pathological type (others vs well and mod)	1.53 (1.19-1.96)	< 0.001
Pathological type (unknown vs well and mod)	1.45 (0.68-3.09)	0.338
Primary site surgery (yes vs no)	0.30 (0.23-0.39)	< 0.001
Adjuvant chemotherapy (yes vs no)	0.28 (0.21-0.38)	< 0.001
Active cancer (yes vs no)	4.28 (2.94-6.24)	< 0.001
Multiple primary vs single primary	0.94 (0.62-1.44)	0.784
CVC placement (yes vs no)	1.92 (1.44-2.55)	< 0.001
Thrombosis treatment (yes vs no)	0.92 (0.56-1.53)	0.761
Opportunity for diagnosis (symptomatic vs asymptomatic)	1.57 (0.50-4.91)	0.436

KRS: Khorana risk score; CAT: Cancer associated thrombosis; ATE: Arterial thromboembolism; ECOG PS: Eastern Cooperative Oncology Group; GC: Gastric cancer; CRC: Colorectal cancer; Well: Well-differentiated adenocarcinoma; Mod: Moderately differentiated adenocarcinoma; CVC: Central venous catheter; HR: Hazard ratios; CI: Confidence intervals.